Sunday, Nov 8, 2026
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Sport
  • Science and Tech
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • My Space
    • Education Today
    • Reviews
    • Property
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • My Space
  • Reviews
  • Education Today
  • Property
  • Lifestyle
Home | Editorials | Editorial Flawed Vaccination Policy

Editorial: Flawed vaccination policy

States like Telangana opting for global tenders to procure vaccine is a pragmatic decision, given the Centre's opaque policy

By Telangana Today
Published Date - 13 May 2021, 12:00 AM
Editorial: Flawed vaccination policy
whatsapp facebook twitter telegram

The Centre’s vaccination policy fails to inspire confidence among the people who are already reeling under the impact of a devastating second wave of the coronavirus pandemic. The affidavit on Covid-19 vaccine production and distribution plans, submitted by the government to the Supreme Court, is ambiguous, opaque and misleading. It is only after the judicial intervention that the broad contours of the vaccination policy have been made public. It now appears that the glaring gap between demand and supply will not be bridged anytime soon. The affidavit suggests that Serum Institute, which manufactures Covishield, and Bharat Biotech, the makers of Covaxin, can together produce 8.5 crore doses a month. This translates into a maximum daily capacity to administer roughly 28 lakh doses. Even going by the expansion plans, India’s monthly vaccine production may not cross 13 crore doses by July, offering potentially 40 lakh jabs daily. This is of little consolation, if the goal is to vaccinate a majority of the population in the quickest possible time. With only 10 crore persons in the 45-plus age group having received their first doses, and even fewer 2.3 crore their second doses, there is confusion and uncertainty over when the 59 crore population in the 18-44 age group will be covered. From the beginning, the Centre’s vaccination policy has been wobbly and tentative. It is the lack of clarity on the part of the Centre that has prompted some States like Telangana to go for global tender to procure the vaccine on an urgent basis.

Opting for global tenders is a pragmatic decision, given the fact that the United States is already reporting supply gluts. Its Pfizer, Moderna, Johnson & Johnson can help India in accelerating the inoculation coverage. India needs about 9 million doses of the Covid-19 vaccine per day to inoculate all adults by September-October this year. Unfortunately, the current availability is less than one-third of that level. And, the total number of registrations on CoWIN portal is over 19 crore while the number of doses being administered per day, including first and second dose, has fallen to 20 lakh from a high of over 40 lakh doses in early April. At the current pace of inoculation, it would take three months to vaccinate just those who have registered till now. By stating that it would purchase only 50% of the vaccine doses and allow vaccine manufacturers to sell the balance directly to the States and private entities at higher prices, the Centre has virtually abdicated its responsibility in ensuring equitable and smooth distribution of vaccines to all. The failure on the part of the Union government to invest in increasing vaccine production capacity has resulted in a desperate shortage of vaccines.



Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .


Join Our Whatsapp Channel
  • Follow Us :
As preferred source
  • Tags
  • Bharat Biotech
  • Centre’s vaccination policy
  • Covaxin
  • COVID-19 vaccine

Related News

  • Bharat Biotech announces 40 pc price cut for Mosqivac malaria vaccine

    Bharat Biotech announces 40 pc price cut for Mosqivac malaria vaccine

  • Indian-American scientist Vinay Prasad quits FDA role again amid pharma clashes

    Indian-American scientist Vinay Prasad quits FDA role again amid pharma clashes

  • Pandorum teams up with Bharat Biotech subsidiary

    Pandorum teams up with Bharat Biotech subsidiary

  • Hyderabad-based Dr Reddy’s inks pact with Johnson & Johnson to acquire vertigo treatment brand

    Hyderabad-based Dr Reddy’s inks pact with Johnson & Johnson to acquire vertigo treatment brand

Latest News

  • UNESCO denies ties with with Kolkata-based Mass Art in fake Durga Puja pass case

    29 minutes ago
  • HCA members question interim Apex Council’s authority to take key decisions

    1 hour ago
  • Rewind: Gulliver’s Travels at 300 — of Beasts, Men and Others

    1 hour ago
  • Karimnagar: Differently-abled youth critical after suicide bid, alleges harassment by BJP corporator

    1 hour ago
  • Statutory inquiry ordered into irregularities in Journalists Cooperative Housing Society

    1 hour ago
  • Jagan condemns arrest of YSRCP MLC Appi Reddy, alleges misuse of power

    2 hours ago
  • India’s historic feat: Lifting nearly half a billion people out of poverty in 12 years

    2 hours ago
  • Man back from Singapore for nephew’s wedding shot dead by neighbour over parking dispute in Faridabad​‌

    2 hours ago

company

  • Home
  • About Us
  • Contact Us
  • Privacy Policy

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

  • Telangana Today Telangana Today
Telangana Today Telangana Today

© Copyrights 2024 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam

Telangana Today App